Navigation Links
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Date:1/27/2009

PALO ALTO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- In light of an announcement made recently by Astellas Pharma Inc., CV Therapeutics, Inc. (Nasdaq: CVTX) confirmed that it had received a letter dated November 13, 2008 from Astellas setting forth an unsolicited proposal by Astellas to acquire CV Therapeutics at a price of $16.00 per share, subject to due diligence, Astellas board approval and other conditions.

After careful deliberation, with the assistance of its financial and legal advisors, the CV Therapeutics board of directors had, on November 21, 2008, concluded that the Astellas proposal was not in the best interests of CV Therapeutics and its stockholders. Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics, sent a letter dated November 21, 2008 to that effect to Astellas on behalf of the board of directors of CV Therapeutics.

Because Astellas, by its recent announcement, has sought to revive its previously rejected proposal, the CV Therapeutics board of directors will again review developments in the context of the company's strategic plans and the long-term interests of its stockholders, to pursue the best course of action to maximize long-term value for stockholders. As part of its ongoing review of the current market environment and the recent developments relating to CV Therapeutics, the board of CV Therapeutics concluded that it was in the best interests of CV Therapeutics and its stockholders to extend the expiration date of its shareholder rights plan from February 1, 2009 to February 1, 2010. CV Therapeutics will keep its stockholders advised.

Barclays Capital is serving as financial advisor, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The National Model Aviation Museum, located at ... to announce that it has been granted full civilian ... States Air Force. , The certification is the culmination ... spring with an on-site inspection by Sarah Sessions, Museum ... National Museum of the United States Air Force ...
(Date:7/25/2014)... study by researchers from the University of Leicester ... function, unlocking the potential to create new materials ... has been published in the prestigious academic journal ... laser technique to examine in rich detail the ... cluster containing an acetylene molecule and a single ...
(Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology Technology:AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Senior clinical executives from top ... met recently at the US offices of Shire ... for a global competition to recognise and encourage ... The US Clinical Researcher of the Year ...
... disease, brain neurons become clogged with tangled proteins. ... malfunctions in a little-known regulatory system within cells. ... about this particular regulatory system in mice. Such ... other diseases in humans and could eventually provide ...
... 16, 2012 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... families nationwide and internationally, today announced that revenues for 2011 ... in 2010.  The Company announced a gross profit increase in ...
Cached Biology Technology:Quality Standards Established for Competition to Identify Best Researchers in the US 2Study dusts sugar coating off little-known regulation in cells 2Study dusts sugar coating off little-known regulation in cells 3Study dusts sugar coating off little-known regulation in cells 4Cord Blood America Revenues Up 37 Percent to $5.67 Million in 2011 2
(Date:7/28/2014)... University researchers are using magnetic beads and DNA "springs" ... used as microscale models for polymer macromolecules. , The ... theory in the 1950s, can be made as stiff ... interest to materials scientists who study the basic physics ... and biomolecular engineer Sibani Lisa Biswal and graduate student ...
(Date:7/28/2014)... help advance the genetic engineering of "fuel" crops ... developed by researchers with the U.S. Department of ... partnership led by Lawrence Berkeley National Laboratory (Berkeley ... that enables scientists to identify and characterize the ... the biosynthesis of plant cell walls. , "Our ...
(Date:7/28/2014)... killers to prevent and treat HIV infection has been ... these molecules can arouse as they get rid of ... the Weizmann Institute and the National Institutes of Health ... molecules interferons around the time of infection ... disease. Their research appeared in Nature . ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2How sweet it is 2How sweet it is 3Interfering with interferon 2
... has identified a genetic variant that substantially increases the ... populations. The study, published by Cell Press on August ... , associates a deletion on chromosome 3 with increased ... that affects 1% of the world population. Characterized by ...
... scientists have been able to measure the amount of water that ... result -- 285 billion metric tons, or 285 cubic kilometers of ... over half the volume of Lake Erie, which is the world,s ... of the water flowing through the Amazon River every year, and ...
... Swine Flu. Rabies. These are emerging infectious diseases where ... another and now infect humans. This is a phenomenon ... to determine what drives it. Gary McCracken, a ... head in Ecology and Evolutionary Biology, is one of ...
Cached Biology News:Large risk schizophrenia marker revealed 2First satellite measurement of water volume in Amazon floodplain 2First satellite measurement of water volume in Amazon floodplain 3UT professor uncovers clues into how viruses jump from hosts 2
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Siglec-9 Biotinylated Affinity Purified Pab...
... an inhibitor of caspase-3/7 ... of inhibitor required to ... be determined empirically for ... inhibitor is sufficient to ...
Human RELT/TNFRSF19L MAb (Clone 238104)...
Biology Products: